{"hands_on_practices": [{"introduction": "The journey of an mRNA molecule from transcription to translation begins with a crucial modification: the addition of a 7-methylguanosine cap to its 5' end. This exercise moves beyond pathway diagrams to quantify the physical consequence of this event. By applying the principle of mass conservation, you will perform a fundamental calculation to determine the net mass increase as a nascent transcript is converted into its capped form, reinforcing your understanding of the molecular building blocks involved. [@problem_id:2579246]", "problem": "A purified $50$-nucleotide messenger ribonucleic acid (mRNA) synthesized by a DNA-dependent RNA polymerase is isolated in its nascent form with a $5'$ triphosphate terminus, denoted $5'-ppp\\mathrm{N}$ where $\\mathrm{N}$ is the first ribonucleotide. In the canonical eukaryotic capping reaction, the following occur in sequence on the same RNA molecule: (i) an RNA $5'$-triphosphatase removes the terminal $\\gamma$-phosphate from the $5'$ end to yield $5'-pp\\mathrm{N}$; (ii) a guanylyltransferase transfers guanosine monophosphate from guanosine triphosphate (GTP) to the $5'$ diphosphate RNA to form the $5'-5'$ triphosphate linkage, yielding $m^{7}\\mathrm{G}ppp\\mathrm{N}$ after (iii) an S-adenosyl-L-methionine (SAM)-dependent methyltransferase adds a single methyl group at the $\\mathrm{N}7$ position of the capping guanine base.\n\nStarting from first principles that (a) molar mass is conserved across reactions and equals the sum of constituent atomic masses, and (b) the $5'-5'$ capping rearranges the distribution of phosphate groups such that the total number of phosphate groups at the $5'$ end is $3$ both before ($5'-ppp\\mathrm{N}$) and after capping ($m^{7}\\mathrm{G}ppp\\mathrm{N}$), compute the net increase in mass of the RNA molecule upon complete conversion from $5'-ppp\\mathrm{N}$ to $m^{7}\\mathrm{G}ppp\\mathrm{N}$. Assume that:\n- The only net additions to the polymer are one guanosine nucleoside and one methyl group (the transient loss of the terminal phosphate in step (i) is balanced by the phosphate introduced with the transferred guanylyl group in step (ii), leaving the total phosphate count unchanged relative to the initial $5'$ triphosphate terminus).\n- Use average atomic masses: carbon $C$: $12.011$, hydrogen $H$: $1.008$, nitrogen $N$: $14.007$, oxygen $O$: $15.999$ (in $\\mathrm{g}\\,\\mathrm{mol}^{-1}$).\n- Use the guanosine nucleoside empirical formula $C_{10}H_{13}N_{5}O_{5}$.\n- Treat the added methyl group as $CH_{3}$.\n\nExpress the final result as the net mass increase in Daltons (Da), rounded to four significant figures. State only the numerical value for the final answer; do not include units in the final boxed answer.", "solution": "The problem requires the calculation of the net increase in mass of a messenger ribonucleic acid (mRNA) molecule upon undergoing the canonical eukaryotic capping process.\n\nFirst, the validity of the problem statement must be established.\nThe problem provides a detailed description of the biochemical pathway for mRNA capping, starting from a nascent transcript with a $5'$ triphosphate terminus ($5'-ppp\\mathrm{N}$) and ending with a methylated guanosine cap ($m^{7}\\mathrm{G}ppp\\mathrm{N}$). All necessary data, including empirical formulas and atomic masses, are supplied. The problem is scientifically grounded in established biochemistry, well-posed, and objective. It contains a critical simplifying assumption: \"Assume that: The only net additions to the polymer are one guanosine nucleoside and one methyl group\". This assumption provides an explicit directive for the calculation, simplifying the complex stoichiometry of the multi-step enzymatic reaction. While an oversimplification of the true atomic balance (which would involve accounting for water molecules in hydrolysis/condensation and the exact composition of released phosphate species), it is a common pedagogical tool to focus the problem on specific concepts. The assumption does not create a logical contradiction or factual impossibility within the problem's context. The problem is therefore deemed valid, and the solution must strictly adhere to this provided assumption.\n\nThe task is to compute the net mass increase, $\\Delta M$. Based on the explicit assumption, this is the sum of the mass of one guanosine nucleoside ($M_{\\text{guanosine}}$) and one methyl group ($M_{\\text{methyl}}$).\n$$\n\\Delta M = M_{\\text{guanosine}} + M_{\\text{methyl}}\n$$\nWe calculate each of these masses using the provided atomic masses: Carbon ($M_C = 12.011 \\, \\mathrm{Da}$), Hydrogen ($M_H = 1.008 \\, \\mathrm{Da}$), Nitrogen ($M_N = 14.007 \\, \\mathrm{Da}$), and Oxygen ($M_O = 15.999 \\, \\mathrm{Da}$).\n\nFirst, we calculate the mass of the guanosine nucleoside, for which the empirical formula is given as $C_{10}H_{13}N_{5}O_{5}$.\n$$\nM_{\\text{guanosine}} = 10 \\times M_C + 13 \\times M_H + 5 \\times M_N + 5 \\times M_O\n$$\nSubstituting the given atomic masses:\n$$\nM_{\\text{guanosine}} = 10 \\times 12.011 + 13 \\times 1.008 + 5 \\times 14.007 + 5 \\times 15.999\n$$\n$$\nM_{\\text{guanosine}} = 120.11 + 13.104 + 70.035 + 79.995\n$$\n$$\nM_{\\text{guanosine}} = 283.244 \\, \\mathrm{Da}\n$$\n\nNext, we calculate the mass of the methyl group, which is given as $CH_{3}$.\n$$\nM_{\\text{methyl}} = 1 \\times M_C + 3 \\times M_H\n$$\nSubstituting the given atomic masses:\n$$\nM_{\\text{methyl}} = 1 \\times 12.011 + 3 \\times 1.008\n$$\n$$\nM_{\\text{methyl}} = 12.011 + 3.024\n$$\n$$\nM_{\\text{methyl}} = 15.035 \\, \\mathrm{Da}\n$$\n\nThe total net increase in mass is the sum of these two components.\n$$\n\\Delta M = M_{\\text{guanosine}} + M_{\\text{methyl}} = 283.244 + 15.035\n$$\n$$\n\\Delta M = 298.279 \\, \\mathrm{Da}\n$$\n\nThe problem requires the final result to be rounded to four significant figures. The calculated value is $298.279$. The first four significant figures are $2$, $9$, $8$, and $2$. The fifth digit is $7$, which is greater than or equal to $5$, so we round up the fourth significant digit.\n$$\n\\Delta M \\approx 298.3 \\, \\mathrm{Da}\n$$\nThe information regarding the length of the mRNA ($50$ nucleotides) is extraneous to the calculation, as the capping modification occurs only at the $5'$ terminus and its mass effect is independent of the polymer's length.", "answer": "$$\n\\boxed{298.3}\n$$", "id": "2579246"}, {"introduction": "At the other end of the pre-mRNA, the 3' cleavage and polyadenylation machinery ensures proper termination and prepares the transcript for its life in the cytoplasm. This practice challenges you to think like a quantitative cell biologist, scaling up from the properties of a single enzyme to the capacity of the entire nucleus. Using fundamental kinetic and cellular parameters, you will calculate the maximum rate at which the key endonuclease, CPSF73, can process transcripts, providing a powerful glimpse into the cell's gene expression throughput. [@problem_id:2579228]", "problem": "A mammalian cell nucleus carries out co-transcriptional messenger ribonucleic acid (mRNA) 3'-end processing by Cleavage and Polyadenylation Specificity Factor 73 (CPSF73), the endonuclease that performs the endonucleolytic cut at the polyadenylation site. Use the following fundamental facts and definitions as the base of your reasoning: (i) the turnover number $k_{\\text{cat}}$ is defined as the number of catalytic events per enzyme molecule per unit time under saturating substrate conditions; (ii) the number of enzyme molecules in a compartment equals the molar concentration times the compartment volume times Avogadro’s constant; (iii) the maximal catalytic capacity at saturation equals the total number of catalytically competent enzyme molecules times $k_{\\text{cat}}$; (iv) one cleavage event is required per transcript; (v) under steady-state transcription, the instantaneous per-gene capacity equals the total maximal cleavage capacity divided uniformly among all simultaneously active genes that require cleavage.\n\nConsider a cell with the following parameters:\n- Nuclear CPSF73 concentration $[\\text{CPSF73}]_{\\text{nuc}} = 50\\ \\text{nM}$.\n- Nuclear volume $V_{\\text{nuc}} = 500\\ \\text{fL}$.\n- Avogadro’s constant $N_{A} = 6.022 \\times 10^{23}\\ \\text{mol}^{-1}$.\n- CPSF73 turnover number $k_{\\text{cat}} = 1.2\\ \\text{s}^{-1}$ when assembled in the cleavage complex at saturating pre-messenger ribonucleic acid (pre-mRNA) substrate.\n- Fraction of nuclear CPSF73 assembled into catalytically competent cleavage complexes $f_{\\text{assembly}} = 0.70$.\n- Fraction of assembled CPSF73 that is engaged with elongating RNA polymerase II at any instant (and thus able to act at saturation) $f_{\\text{engaged}} = 0.50$.\n- Number of actively transcribed protein-coding genes that undergo cleavage $n_{g} = 12000$.\n\nAssume steady-state transcription with abundant pre-messenger ribonucleic acid reaching polyadenylation sites so that CPSF73 operates at saturation wherever it is engaged, and that each active gene draws equally on the available engaged cleavage capacity at any instant.\n\nCompute the maximal cleavage capacity per gene per minute. Express your final answer in molecules min$^{-1}$ gene$^{-1}$. Round your answer to three significant figures.", "solution": "The problem requires the calculation of the maximal cleavage capacity per gene per minute for the endonuclease CPSF73 under specified cellular conditions. First, a validation of the problem statement is in order.\n\nStep 1: Extract Givens\nThe following data and definitions are provided:\n- Definition (i): The turnover number $k_{\\text{cat}}$ is the number of catalytic events per enzyme molecule per unit time at saturation.\n- Definition (ii): Number of enzyme molecules = molar concentration $\\times$ compartment volume $\\times$ Avogadro’s constant.\n- Definition (iii): Maximal catalytic capacity at saturation = total catalytically competent enzyme molecules $\\times$ $k_{\\text{cat}}$.\n- Definition (iv): One cleavage event is required per transcript.\n- Definition (v): Per-gene capacity = total maximal cleavage capacity divided uniformly among all simultaneously active genes.\n- Nuclear CPSF73 concentration, $[\\text{CPSF73}]_{\\text{nuc}} = 50\\ \\text{nM}$.\n- Nuclear volume, $V_{\\text{nuc}} = 500\\ \\text{fL}$.\n- Avogadro’s constant, $N_{A} = 6.022 \\times 10^{23}\\ \\text{mol}^{-1}$.\n- CPSF73 turnover number, $k_{\\text{cat}} = 1.2\\ \\text{s}^{-1}$.\n- Fraction of nuclear CPSF73 in competent complexes, $f_{\\text{assembly}} = 0.70$.\n- Fraction of assembled CPSF73 engaged and active, $f_{\\text{engaged}} = 0.50$.\n- Number of active genes, $n_{g} = 12000$.\n- Assumptions: Steady-state transcription, saturation conditions for engaged CPSF73, and equal distribution of capacity among genes.\n\nStep 2: Validate Using Extracted Givens\nThe problem is evaluated for validity.\n- **Scientifically Grounded:** The problem is firmly rooted in the principles of enzyme kinetics and molecular cell biology, specifically the process of mRNA 3'-end formation. The components (CPSF73, pre-mRNA, RNA Polymerase II) and parameters (concentration, volume, turnover rate) are standard and their values are within biologically plausible ranges for a mammalian cell. The problem is scientifically sound.\n- **Well-Posed:** All necessary data and definitions are provided to compute a unique solution. The objective is clearly stated.\n- **Objective:** The language is technical and precise, free from subjective or ambiguous statements.\n\nStep 3: Verdict and Action\nThe problem is deemed **valid**. A systematic solution will now be constructed.\n\nThe objective is to compute the maximal cleavage capacity per gene, which we denote as $C_{\\text{per gene}}$, in units of molecules per minute per gene. This requires a multi-step calculation based on the provided definitions.\n\nFirst, we determine the total number of CPSF73 molecules in the nucleus, $N_{\\text{total}}$. According to definition (ii), this is the product of concentration, volume, and Avogadro's constant. The units must be consistent. We convert the concentration from nanomolar ($nM$) to molar ($M$) and the volume from femtoliters ($fL$) to liters ($L$).\n$$[\\text{CPSF73}]_{\\text{nuc}} = 50\\ \\text{nM} = 50 \\times 10^{-9}\\ \\text{mol} \\cdot \\text{L}^{-1}$$\n$$V_{\\text{nuc}} = 500\\ \\text{fL} = 500 \\times 10^{-15}\\ \\text{L} = 5 \\times 10^{-13}\\ \\text{L}$$\nThe total number of molecules is:\n$$N_{\\text{total}} = [\\text{CPSF73}]_{\\text{nuc}} \\times V_{\\text{nuc}} \\times N_{A}$$\n\nNext, we calculate the number of CPSF73 molecules that are both catalytically competent and actively engaged. This subset of enzymes is responsible for the cell's total cleavage capacity. The problem provides two fractions: $f_{\\text{assembly}}$, the fraction assembled into competent complexes, and $f_{\\text{engaged}}$, the fraction of those complexes that are engaged with RNA polymerase II and thus operating at saturation. The number of active enzyme molecules, $N_{\\text{active}}$, is therefore:\n$$N_{\\text{active}} = N_{\\text{total}} \\times f_{\\text{assembly}} \\times f_{\\text{engaged}}$$\n$$N_{\\text{active}} = ([\\text{CPSF73}]_{\\text{nuc}} \\times V_{\\text{nuc}} \\times N_{A}) \\times f_{\\text{assembly}} \\times f_{\\text{engaged}}$$\n\nThe total maximal cleavage capacity of the nucleus, $C_{\\text{total}}$, is the product of the number of active enzyme molecules and their turnover number, $k_{\\text{cat}}$, as per definition (iii).\n$$C_{\\text{total}} = N_{\\text{active}} \\times k_{\\text{cat}}$$\nThe units of $C_{\\text{total}}$ will be events per second, which is equivalent to molecules cleaved per second, given that one event processes one molecule.\n\nAccording to definition (v), this total capacity is distributed uniformly among all $n_{g}$ actively transcribed genes. The maximal cleavage capacity per gene, $C_{\\text{per gene}}$, is:\n$$C_{\\text{per gene}} = \\frac{C_{\\text{total}}}{n_{g}} = \\frac{([\\text{CPSF73}]_{\\text{nuc}} \\times V_{\\text{nuc}} \\times N_{A}) \\times f_{\\text{assembly}} \\times f_{\\text{engaged}} \\times k_{\\text{cat}}}{n_{g}}$$\nThis expression gives the capacity in units of molecules gene$^{-1}$ s$^{-1}$. The final answer must be in molecules gene$^{-1}$ min$^{-1}$. We must therefore multiply the result by a conversion factor of $60\\ \\text{s} \\cdot \\text{min}^{-1}$.\n$$C_{\\text{per gene, min}} = C_{\\text{per gene}} \\times 60$$\n\nNow, we substitute the numerical values into the derived expression:\n$$N_{\\text{active}} = (50 \\times 10^{-9}\\ \\text{mol} \\cdot \\text{L}^{-1}) \\times (5 \\times 10^{-13}\\ \\text{L}) \\times (6.022 \\times 10^{23}\\ \\text{mol}^{-1}) \\times 0.70 \\times 0.50$$\n$$N_{\\text{active}} = (2.5 \\times 10^{-20}\\ \\text{mol}) \\times (6.022 \\times 10^{23}\\ \\text{mol}^{-1}) \\times 0.35$$\n$$N_{\\text{active}} = (15.055 \\times 10^{3}) \\times 0.35$$\n$$N_{\\text{active}} = 15055 \\times 0.35 = 5269.25\\ \\text{molecules}$$\n\nNext, we calculate the total cleavage capacity, $C_{\\text{total}}$, in s$^{-1}$:\n$$C_{\\text{total}} = 5269.25 \\times k_{\\text{cat}} = 5269.25 \\times 1.2\\ \\text{s}^{-1} = 6323.1\\ \\text{s}^{-1}$$\n\nThen, we find the capacity per gene, $C_{\\text{per gene}}$, in s$^{-1}$:\n$$C_{\\text{per gene}} = \\frac{6323.1\\ \\text{s}^{-1}}{12000\\ \\text{genes}} \\approx 0.526925\\ \\text{molecules} \\cdot \\text{gene}^{-1} \\cdot \\text{s}^{-1}$$\n\nFinally, we convert this to the required units of molecules per minute per gene:\n$$C_{\\text{per gene, min}} = 0.526925\\ \\text{molecules} \\cdot \\text{gene}^{-1} \\cdot \\text{s}^{-1} \\times 60\\ \\text{s} \\cdot \\text{min}^{-1}$$\n$$C_{\\text{per gene, min}} \\approx 31.6155\\ \\text{molecules} \\cdot \\text{gene}^{-1} \\cdot \\text{min}^{-1}$$\n\nRounding the result to three significant figures, as required by the problem statement, gives $31.6$.", "answer": "$$\n\\boxed{31.6}\n$$", "id": "2579228"}, {"introduction": "While the canonical capping and polyadenylation pathways are the norm, specialized systems exist for certain gene classes, such as the tightly regulated replication-dependent histone genes. This thought experiment places you at the intersection of these two systems by asking you to predict the fate of a genetically engineered histone mRNA containing a canonical poly(A) signal. To solve this, you must integrate your knowledge of mRNA processing, stability, and translation to determine which regulatory logic will prevail and how you would experimentally verify your conclusions. [@problem_id:2579240]", "problem": "A replication-dependent histone gene normally undergoes specialized $3'$ end formation that produces a non-polyadenylated messenger ribonucleic acid (mRNA) terminating in a conserved stem–loop bound by Stem–Loop Binding Protein (SLBP). This specialized processing requires the U7 small nuclear ribonucleoprotein (U7 snRNP) and a downstream histone downstream element, is independent of the canonical polyadenylation pathway, and yields transcripts that are tightly coupled to deoxyribonucleic acid (DNA) replication: they accumulate in S phase and are rapidly degraded when replication is inhibited. By contrast, canonical cleavage and polyadenylation require the cleavage and polyadenylation specificity factor (CPSF) recognizing the AAUAAA hexamer and generate a poly(A) tail that recruits cytoplasmic poly(A)-binding protein (PABP), which both protects the $3'$ end from exonucleases and promotes translation initiation through interactions with eukaryotic initiation factor 4E (eIF4E) and eukaryotic initiation factor 4G (eIF4G).\n\nYou engineer a canonical AAUAAA polyadenylation signal into the $3'$ untranslated region of a replication-dependent histone gene downstream of its stem–loop, at the endogenous locus, such that cleavage and polyadenylation can compete with or replace the histone-specific processing pathway. In a clonal cell line expressing only this engineered allele, you synchronize cells and then inhibit DNA replication with hydroxyurea. You also have access to standard assays, including oligo(dT) selection, $3'$ rapid amplification of complementary DNA ends ($3'$ RACE), Northern blotting, ribosome profiling, polysome gradient fractionation, RNA stability measurements after transcriptional shutoff, small interfering ribonucleic acid (siRNA) knockdown of SLBP or PABP, and size analysis of poly(A) tails by poly(A) test (PAT) assays.\n\nBased on the fundamental definitions of eukaryotic mRNA $5'$ capping, $3'$ end formation, replication-dependent histone mRNA metabolism, and the well-established roles of poly(A) tails and PABP in mRNA stability and translation, which of the following integrated prediction-plus-measurement packages is most consistent with biochemical first principles?\n\nA. The engineered transcript is cleaved and polyadenylated, uncoupling it from S-phase–restricted accumulation and from rapid decay upon replication block. Its steady-state abundance increases outside S phase due to increased stability, and translation proceeds efficiently via the PABP–eIF4E/eIF4G closed-loop mechanism with reduced dependence on SLBP. Measurable outcomes: positive enrichment by oligo(dT) selection and detection by $3'$ RACE at the polyadenylation site; prolonged mRNA half-life and persistence after hydroxyurea; insensitivity of $3'$ end formation to U7 snRNP perturbation; maintained or increased association with heavy polysomes that is sensitive to PABP knockdown but relatively insensitive to SLBP knockdown; and detectable histone protein accumulation beyond S phase.\n\nB. The engineered transcript becomes nuclear-retained and destabilized because the histone stem–loop is no longer at the extreme $3'$ terminus, preventing nuclear export, and the acquired poly(A) tail accelerates decay by recruiting deadenylases. Measurable outcomes: reduced cytoplasmic abundance and shorter half-life than wild type; no enrichment by oligo(dT) selection; decreased polysome association; and heightened sensitivity of decay to hydroxyurea.\n\nC. The engineered transcript is polyadenylated but remains fully S-phase coupled because SLBP still binds the stem–loop upstream of the new poly(A) site, thereby dictating replication-responsive decay. Measurable outcomes: rapid loss of the polyadenylated histone mRNA upon hydroxyurea treatment, no detection outside S phase, and unchanged dependence of polysome association on SLBP with no effect of PABP knockdown.\n\nD. The engineered transcript is cleaved and polyadenylated, which stabilizes the mRNA but strongly represses translation because the $3'$ stem–loop no longer directly promotes initiation. Measurable outcomes: strong oligo(dT) enrichment and prolonged half-life that do not change with hydroxyurea, but a shift out of polysomes and reduced ribosome footprints per mRNA that are alleviated by SLBP overexpression and unaffected by PABP knockdown; no change in histone protein levels outside S phase.", "solution": "The problem statement will be validated before a solution is attempted.\n\n**Step 1: Extract Givens**\n\n- **Wild-type System:** Replication-dependent histone genes produce a non-polyadenylated messenger ribonucleic acid (mRNA) that terminates in a conserved stem–loop structure.\n- **Wild-type Processing:** This specialized $3'$ end processing is dependent on the U7 small nuclear ribonucleoprotein (U7 snRNP) and a histone downstream element (HDE). It is independent of the canonical polyadenylation pathway.\n- **Wild-type Regulation:** The stem–loop is bound by the Stem–Loop Binding Protein (SLBP). The resulting mRNA transcripts accumulate during S phase of the cell cycle and are rapidly degraded upon inhibition of deoxyribonucleic acid (DNA) replication.\n- **Canonical Polyadenylation:** This standard pathway requires the cleavage and polyadenylation specificity factor (CPSF) to recognize an AAUAAA signal. It generates a poly(A) tail that recruits the cytoplasmic poly(A)-binding protein (PABP).\n- **PABP Functions:** PABP protects the mRNA $3'$ end from exonucleases (enhancing stability) and promotes translation initiation through interactions with eukaryotic initiation factor 4E (eIF4E) and eukaryotic initiation factor 4G (eIF4G), forming a \"closed loop\".\n- **Engineered System:** A canonical AAUAAA polyadenylation signal has been introduced into the $3'$ untranslated region of a replication-dependent histone gene, located downstream of the native stem–loop structure.\n- **Experimental Context:** A clonal cell line expresses only this engineered allele. Experiments involve cell synchronization and inhibition of DNA replication using hydroxyurea. A range of standard molecular biology assays are available.\n- **Core Question:** The question asks for the most consistent prediction of the engineered system's behavior, based on the established principles of eukaryotic mRNA metabolism.\n\n**Step 2: Validate Using Extracted Givens**\n\n- **Scientific Grounding:** The problem is firmly rooted in established principles of molecular biology and biochemistry. The descriptions of histone mRNA processing, canonical polyadenylation, and the functions of SLBP, PABP, U7 snRNP, and the poly(A) tail are all factually correct and represent textbook knowledge.\n- **Well-Posedness:** The problem describes a hypothetical but experimentally feasible genetic modification and asks for a prediction of its consequences. The setup is clearly defined, allowing for a logical deduction based on the interplay of known molecular mechanisms. A unique, principled outcome can be derived.\n- **Objectivity:** The language is technical, precise, and free from subjective or biased statements.\n- **Flaw Analysis:**\n    - The problem does not violate any fundamental scientific principles.\n    - The problem is highly relevant to the field of biochemistry and molecular genetics and is not metaphorical.\n    - The setup is self-contained and provides sufficient information. The key detail is the placement of the poly(A) signal *downstream* of the stem–loop, which defines the central conflict between the two processing/regulatory pathways.\n    - The described genetic engineering and subsequent experiments are standard and feasible.\n    - The terminology is unambiguous within the context of the field.\n    - The problem requires a non-trivial integration of multiple concepts: mRNA processing, mRNA stability, cell cycle regulation, and translation control.\n\n**Step 3: Verdict and Action**\n\nThe problem statement is **valid**. It is scientifically sound, well-posed, and based on established principles. The solution process may proceed.\n\n**Solution Derivation**\n\nThe engineered construct presents two competing pathways for $3'$ end processing of the histone pre-mRNA.\n\n$1$. **Histone-specific cleavage:** Mediated by U7 snRNP at the site between the stem-loop and the HDE. This produces the traditional, non-polyadenylated, replication-dependent histone mRNA.\n$2$. **Canonical cleavage and polyadenylation:** Mediated by CPSF at the newly inserted AAUAAA signal, which lies downstream of the histone processing site. This will produce a longer mRNA isoform that contains the histone stem-loop followed by a poly(A) tail.\n\nThe problem states that the canonical pathway can \"compete with or replace\" the histone pathway. Given the robustness of the canonical polyadenylation machinery, it is a certainty that a significant population of transcripts will be processed at this new site. We must analyze the fate of this novel, polyadenylated histone mRNA.\n\n**Regulation of Stability:**\nThe wild-type histone mRNA is rapidly degraded outside of S phase via a mechanism dependent on the SLBP-bound stem-loop. The new, polyadenylated transcript contains this same stem-loop/SLBP complex. However, it also possesses a $3'$ poly(A) tail, which will be bound by PABP. A fundamental role of the PABP-poly(A) complex is to protect the mRNA from exonucleolytic decay, thereby greatly increasing its half-life. It acts as a potent stabilizing element. In a direct conflict between the SLBP-mediated degradation signal and the PABP-mediated stabilization signal on the same molecule, it is biochemically most probable that the stabilizing effect of PABP will dominate or at least severely antagonize the decay pathway. Consequently, the polyadenylated histone mRNA is expected to be significantly more stable and to lose its tight coupling to S-phase-dependent degradation. It should persist even after DNA replication is blocked by hydroxyurea.\n\n**Regulation of Translation:**\nWild-type histone mRNA translation is promoted by SLBP. The new, polyadenylated mRNA has two elements that can promote translation: the SLBP bound to the internal stem-loop and the PABP bound to the $3'$ poly(A) tail. The PABP-mediated mechanism, involving interaction with eIF4G at the $5'$ cap to form a closed-loop, is a general and highly efficient mechanism for promoting translation initiation in eukaryotes. The presence of this potent pathway means the engineered mRNA should be translated efficiently. Its dependence on the SLBP-mediated pathway for translation is likely to be reduced, as the canonical PABP pathway provides a robust alternative or supplement.\n\n**Summary of Predictions:**\n- A substantial fraction of histone transcripts will be polyadenylated. This can be verified by oligo(dT) selection and $3'$ RACE.\n- These polyadenylated transcripts will have a longer half-life than their non-polyadenylated counterparts and will not be rapidly degraded upon replication arrest.\n- Histone mRNA and, consequently, histone protein will accumulate outside of S phase.\n- The mRNA will be associated with polysomes, indicating active translation. This translation will be dependent on PABP. Knockdown of PABP should decrease translation, while knockdown of SLBP may have a reduced effect compared to the wild-type situation.\n- The formation of the polyadenylated $3'$ end will be independent of the U7 snRNP machinery.\n\n**Option-by-Option Analysis**\n\n**A.** This option predicts cleavage and polyadenylation, uncoupling from S-phase accumulation, increased stability, and efficient translation via the PABP-eIF4E/eIF4G mechanism. The proposed measurable outcomes directly test these predictions: oligo(dT) enrichment and correct $3'$ RACE product confirm polyadenylation; prolonged half-life and persistence after hydroxyurea confirm stabilization and uncoupling; insensitivity to U7 snRNP perturbation confirms use of the canonical pathway; PABP-sensitive polysome association confirms the translation mechanism; and histone protein accumulation beyond S phase is the final downstream consequence. This package is entirely consistent with the derived principles. **Correct.**\n\n**B.** This option predicts nuclear retention and destabilization. The premise that an internal stem-loop blocks nuclear export is speculative and unlikely, particularly since the transcript now has a poly(A) tail, which promotes export. The claim that the poly(A) tail \"accelerates decay\" is a direct contradiction of its primary role in mRNA stability. The predicted outcomes (shorter half-life, no oligo(dT) enrichment) are inconsistent with the initial premise of polyadenylation and its known functions. **Incorrect.**\n\n**C.** This option predicts that the transcript is polyadenylated but remains fully S-phase coupled. This assumes the SLBP-mediated decay pathway completely overrides the stabilizing function of the PABP-poly(A) complex, which is biochemically improbable. Furthermore, it claims that translation will show \"no effect of PABP knockdown.\" This is fundamentally incorrect, as PABP is a critical general translation factor for polyadenylated mRNAs. **Incorrect.**\n\n**D.** This option correctly predicts stabilization but incorrectly predicts strong repression of translation. It posits that the non-terminal stem-loop becomes a repressor, which is an unsupported claim. More importantly, it ignores the potent translational enhancement provided by the new PABP-bound poly(A) tail. Like options B and C, it makes the fundamentally flawed claim that PABP knockdown would not affect translation. The prediction of \"no change in histone protein levels outside S phase\" is also inconsistent with a stable and translated mRNA. **Incorrect.**", "answer": "$$\\boxed{A}$$", "id": "2579240"}]}